
Home » AstraZeneca Licenses Vanderbilt University’s Monoclonal Antibodies for COVID-19
AstraZeneca Licenses Vanderbilt University’s Monoclonal Antibodies for COVID-19

AstraZeneca has licensed six monoclonal antibodies from Vanderbilt University and plans to advance the most promising ones for prevention and treatment of COVID-19.
Monoclonal antibodies are synthesized versions of natural antibodies that may be able to neutralize the SARS-CoV-2 virus.
The company said it plans to begin a study of two antibodies as a combination treatment within the next two months.
Upcoming Events
-
01Feb
-
08Feb
-
09Feb
-
15Feb
-
16Feb
-
22Feb